Zobrazeno 1 - 10
of 84
pro vyhledávání: '"ERYTHROPOIETIN, RECOMBINANT"'
Autor:
Igor Barbosa da Silva, Paulo César Dick, Katherine Antunes de Mattos, Alessandra Santos Almeida, Ricardo Gonçalves Silva, Darcy Akemi Hokama, Francisco José Roma Paumgartten
Publikováno v:
Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, Vol 1, Iss 3, Pp 49-58 (2013)
Neste estudo comparamos os resultados de ensaios de potência da alfaepoetina (EPOhr) realizados com camundongos de diferentes colônias e linhagens (Swiss Webster, NIH, C57BL/6 e BALB/c) com aqueles de ensaios conduzidos com o híbrido B6D2F1, o ún
Externí odkaz:
https://doaj.org/article/1e799549ffb2472e8517c3e95bd77566
Autor:
Tong-heng CHEN, Zi-wei ZHOU, Sheng-jie LI, Ye TIAN, Guo-wei YANG, Shi-zhao WANG, Ming WEI, Ping LEI, Jian-ning ZHANG
Publikováno v:
Chinese Journal of Contemporary Neurology and Neurosurgery, Vol 13, Iss 2, Pp 142-148 (2013)
Background Inflammation after traumatic brain injury (TBI) could exacerbate secondary brain injury, resulting in neuronal apoptosis and neurological deficit. It is confirmed that recombinant human erythropoietin (rhEPO) plays an important role in neu
Externí odkaz:
https://doaj.org/article/c3a821d1fde44178b4a358e9f88de036
Autor:
Knežević Violeta, Milošević Aleksandra, Vodopivec Slavenka, Božić Dušan, Budošan Ivana, Majić Milena
Publikováno v:
Vojnosanitetski Pregled, Vol 68, Iss 9, Pp 749-755 (2011)
Background/Aim. In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis
Externí odkaz:
https://doaj.org/article/f3495ba710e141e698155a827574ea3d
Publikováno v:
Revista Cubana de Medicina, Vol 42, Iss 1, Pp 89-92 (2003)
Se presentó el caso de una paciente de 24 años de edad y raza blanca con antecedentes de nefritis túbulo-intersticial crónica, por lo cual llega a la insuficiencia renal crónica grado IV. Se mantuvo 2 años en métodos dialíticos, recibió un t
Externí odkaz:
https://doaj.org/article/1cfa8f566f404fdeb3364fb354a67d59
Publikováno v:
Revista Cubana de Medicina, Vol 40, Iss 4, Pp 292-296 (2001)
Se presentó el caso de una paciente de 24 años de edad y raza blanca con antecedentes de nefritis túbulo-intersticial crónica, vía por la cual llegó a la insuficiencia renal crónica grado IV. Se mantuvo 2 años en métodos dialíticos y recibi
Externí odkaz:
https://doaj.org/article/25fd7381d4874458a37fa31bac0e1200
Autor:
Slavenka Vodopivec, Ivana Budosan, Aleksandra Milosevic, Dusan Bozic, Milena Majic, Violeta Knezevic
Publikováno v:
Vojnosanitetski Pregled, Vol 68, Iss 9, Pp 749-755 (2011)
Background/Aim. In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis
Autor:
Kai C. Wollert, Agnese Viganò, Tibor Kempf, Paolo Santambrogio, Niels Jacob Aachmann-Andersen, Jonas Juhl Thomsen, Natascia Campostrini, Alessandra Alberghini, Stéphane Moutereau, Carsten Lundby, Stefania Recalcati, Gaetano Cairo, Domenico Girelli, Paul Robach, Annalisa Castagna, Cecilia Gelfi, Anne M. Norgaard
Publikováno v:
ResearcherID
Robach, P, Recalcati, S, Girelli, D, Gelfi, C, Aachmann-Andersen, N J, Norgaard, A M, Alberghini, A, Campostrini, N, Castagna, A, Viganò, A, Santambrogio, P, Kempf, T, Wollert, K C, Moutereau, S, Lundby, C, Cairo, G & Thomsen, J J 2009, ' Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin ', Blood, vol. 113, no. 26, pp. 6707-15 . https://doi.org/10.1182/blood-2008-09-178095
Robach, P, Recalcati, S, Girelli, D, Gelfi, C, Aachmann-Andersen, N J, Norgaard, A M, Alberghini, A, Campostrini, N, Castagna, A, Viganò, A, Santambrogio, P, Kempf, T, Wollert, K C, Moutereau, S, Lundby, C, Cairo, G & Thomsen, J J 2009, ' Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin ', Blood, vol. 113, no. 26, pp. 6707-15 . https://doi.org/10.1182/blood-2008-09-178095
The high iron demand associated with enhanced erythropoiesis during high-altitude hypoxia leads to skeletal muscle iron mobilization and decrease in myoglobin protein levels. To investigate the effect of enhanced erythropoiesis on systemic and muscle
Autor:
Régine Farion, Jean François Payen, Yohan Van De Looij, Olivier Verdonck, Chantal Rémy, Gilles Francony, Christoph Segebarth, Hana Lahrech, Olivier Carle
Publikováno v:
Journal of Cerebral Blood Flow and Metabolism
Journal of Cerebral Blood Flow and Metabolism, Nature Publishing Group, 2007, 27 (7), pp.1369-76. ⟨10.1038/sj.jcbfm.9600443⟩
Journal of Cerebral Blood Flow and Metabolism, Nature Publishing Group, 2007, 27 (7), pp.1369-76. ⟨10.1038/sj.jcbfm.9600443⟩
Erythropoietin (Epo) is gaining interest in various neurological insults as a possible neuroprotective agent. We determined the effects of recombinant human Epo (rhEpo, 5000 IU per kg bw) on brain edema induced in rats by traumatic brain injury (TBI;
Publikováno v:
Biochim. Biophys. Acta Mol. Cell Res. 2006;1763(2):238-246
Biblioteca Digital (UBA-FCEN)
Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
instacron:UBA-FCEN
Biblioteca Digital (UBA-FCEN)
Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
instacron:UBA-FCEN
Since apoptosis appeared to be related to neurodegenerative processes, neuroprotection has been involved in investigation of therapeutic approaches focused upon pharmacological agents to prevent neuronal programmed cell death. In this regard, erythro
Autor:
Belgin Buyukakilli, Arzu Kanik, Anthony Cerami, Raffaella Lombardi, Pietro Ghezzi, Giuseppe Lauria, Guido Cavaletti, Roberto Bianchi, Norberto Oggioni, Burak Çimen, Michael Brines, M Borgna, Ulku Comelekoglu, Cengiz Tataroglu, Costanza Savino
Publikováno v:
Proceedings of the National Academy of Sciences. 101:823-828
Erythropoietin (EPO) possesses generalized neuroprotective and neurotrophic actions. We tested the efficacy of recombinant human EPO (rhEPO) in preventing and reversing nerve dysfunction in streptozotocin (STZ)-induced diabetes in rats. Two days afte